Name: CTLA-4 Fc Fusion Protein (Belatacept Biosimilar)
Brand: InnoCyto
SKU: 500801
Price: 400 USD
Availability: InStock

Shop Now Contact

CTLA-4 Fc Fusion Protein (Belatacept Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
500801	1 mg	$400
500802	5 mg	$800
500803	20 mg	$1600

Bulk/Custom

Product Details

Clone	Belatacep
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Format	Liquid
Product Description	CTLA-4 Fc Fusion Protein (Belatacept Biosimilar)
Isotype	Human IgG1
Regulatory Status	RUO
Clonality	Recombinant
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Min Sample Size	1 mg
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Synonyms	CD152
RRID	AB_3739284
Target Name	CTLA4, CD152, CELIAC3, GSE, IDDM12
Research Areas	Tregs, Activated T cells, Autoimmunity, Immune Checkpoints, Cancer Immunology
See All Formats	Clone Belatacep

Background Information

Belatacept is a recombinant fusion protein designed to modulate T-cell activation through selective interference with costimulatory signaling. Structurally, it combines the extracellular domain of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4, also known as CD152) with the Fc (fragment crystallizable) region of human immunoglobulin G1 (IgG1). This molecular architecture creates a chimeric protein with high affinity and stability, mimicking natural receptor interactions while maintaining the durability of an antibody framework. The molecule has a molecular mass of approximately 92 kilodaltons (kDa) and is produced using recombinant DNA technology in mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, to ensure proper folding, disulfide bond formation, and glycosylation characteristic of human proteins.

The functional core of Belatacept resides in its CTLA-4 domain, which binds specifically to the costimulatory ligands CD80 (B7-1) and CD86 (B7-2) expressed on antigen-presenting cells (APCs). These ligands normally interact with the CD28 receptor on T cells to deliver the second signal required for full T-cell activation, following antigen recognition. By binding to CD80 and CD86 with high affinity, Belatacept blocks their interaction with CD28, effectively preventing the costimulatory signal and leading to inhibition of T-cell activation, proliferation, and cytokine production. This mechanism allows fine control of immune cell signaling without direct cytotoxicity.

The Fc region of Belatacept, derived from human IgG1, confers structural stability, facilitates dimerization via interchain disulfide bonds, and contributes to a prolonged half-life through interaction with the neonatal Fc receptor (FcRn), which protects the molecule from lysosomal degradation. Importantly, the IgG1 Fc segment in Belatacept is engineered to minimize effector functions such as complement activation and antibody-dependent cellular cytotoxicity. Overall, Belatacept exemplifies rational protein engineering, combining receptor-mimicking precision with antibody-derived pharmacokinetic efficiency to enable controlled modulation of T-cell costimulatory pathways in immunological research.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips